Ariosa Diagnostics Welcomes New Board Member Michael A. Aicher

Download PDF

San Jose, Calif., February 25, 2013 – Ariosa Diagnostics, maker of the non-invasive Harmony™
Prenatal Test for detection of common genetic conditions, has announced the election of
Michael A. Aicher to its Board of Directors.

Mr. Aicher has had a very successful career in the molecular diagnostics industry having spent
the last 20 years in leadership positions at National Genetics Institute (NGI), a wholly-owned
subsidiary of Laboratory Corporation of America® Holdings (LabCorp®), and LabCorp.

As the co-founder and CEO of NGI, Mr. Aicher steered the implementation of an initial treatment
model for HCV and secured the first FDA-approved HIV/HCV PCR tests for plasma donor
screening, with 15 million donations per year tested. Under various leadership positions at
LabCorp, he helped drive revenue and margins within the esoteric testing business. Recognition
for Mr. Aicher includes distinction as an Ernst & Young “Entrepreneur of the Year” for Emerging
Technologies. Mr. Aicher recently took on the CEO position at Omicia, a DNA sequencing
informatics company.

“Ariosa Diagnostics is honored to welcome Michael Aicher to the board. His multiple fields of
expertise in strategy and operations within molecular testing will greatly complement the existing
board. We are pleased that he will share his leadership and guidance with the team at Ariosa,”
said Ken Song, MD, CEO of Ariosa.